FAQ: Nutriband Inc. CEO Return and AVERSA Fentanyl Development

What is the main announcement in this press release?

Nutriband Inc. announced that company founder Gareth Sheridan has resumed his role as CEO effective immediately, replacing Co-Founder and Chairman Serguei Melnik who temporarily served in the position.

What is AVERSA Fentanyl and what does it do?

AVERSA Fentanyl is Nutriband’s flagship abuse-deterrent opioid patch designed to prevent misuse, abuse, diversion, and accidental exposure of fentanyl through their proprietary AVERSA technology.

When is the expected timeline for AVERSA Fentanyl’s regulatory filing?

Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA (New Drug Application) filing for AVERSA Fentanyl.

What is the commercial potential for AVERSA Fentanyl?

Potential peak annual U.S. sales for AVERSA Fentanyl are estimated between $80 million and $200 million.

How is the AVERSA technology protected?

The AVERSA technology is protected by patents in 46 countries, including the United States, Europe, and Japan.

What is Nutriband Inc.’s primary business focus?

Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with AVERSA Fentanyl as their lead product under development.

Where can investors find more information about Nutriband?

The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the company’s website is www.nutriband.com.

What broader applications does the AVERSA technology have?

The AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Why is this leadership change significant for investors?

The return of founder Gareth Sheridan as CEO signals focused leadership during the critical final development phase leading to the 2026 NDA filing, which is a major milestone for the company’s flagship product.